14 Exploring real-world concordance of tumor mutation burden (TMB) from blood and tissue in patients with solid tumors

Oh, Youjin; Park, Jewel; Chung, Liam Il-Young; Lee, Soowon; Hong, Timothy; Chae, Young Kwang

doi:10.1136/jitc-2022-sitc2022.0014

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence by cancer type was correlated with prevalence of elevated tissue TMB (r = 0.81). While there are some reports of high correlation in lung cancer, there are also reports of low correlation and concordance rates in gastrointestinal cancer, and differences by metastatic organ have also been reported [ 27 , 28 ]. Further investigation of bTMB is needed.…”

Section: Resultsmentioning

confidence: 99%

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors

Mishima¹,

Naito²,

Akagi³

et al. 2023

Int J Clin Oncol

View full text Add to dashboard Cite

The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%